Artigos

Search for articles

BJO Oncology - Placeholder

Delayed and sequencial hemolytic uremic syndrome as a complication of Gemcitabine therapy

ABSTRACT Gemcitabine is a widely used drug in the treatment of diverse malignancies and its use has been approved by the US Food and Drug Administration. This drug has been associated with a rare adverse event, the Hemolytic Uremic Syndrome (HUS), characterized by acute kidney injury, microangiopathic hemolytic anemia, and...
BJO Oncology - Placeholder

Using chemotherapy against metastatic pancreatic neuroendocrine neoplasm: how aggressively do we treat it? Real world data from a Brazilian Cancer Center

ABSTRACT Introduction: Pancreatic neuroendocrine neoplasms (pNEN) have poor prognosis. Available treatment options are limited. We aimed to evaluate the clinical characteristics and outcomes in patients with pNEN undergoing systemic chemotherapy. Methods: Retrospective study of patients with metastatic pNEN diagnosed between January 2000 and April 2018 in A.C. Camargo Cancer Center. We evaluated...
BJO Oncology - Placeholder

COVID-19 among cancer patients. What we know so far?

ABSTRACT In December 2019, a novel coronavirus disease (COVID-19) emerged in Wuhan, a city in the Hubei, Province of China. It rapidly spread in an epidemic fashion throughout China, followed by rapid increasing number of cases in many countries throughout the world, including Brazil. It is expected that oncologic patients...